Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05457491 · ClinicalTrials.gov registry record · Phase 1
Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE)
A Phase 1 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT05457491: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT05457491 is a Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 56 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05457491, a Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
The Researchers are trying to study a cosmetic skin care product called human platelet extract (HPE) to see if it can be used as a possible treatment for skin anti-aging and skin rejuvenation. They are trying find out the safety and tolerability of topical HPE after multiple doses of topical administration
Primary Outcome
The percentage of participants to experience at least 50% improvement in redness area over baseline. As measured by photodocumentation with the VISIA-CR Generation 5 3D PRIMOS using RBX technology. Redness pixel variation and the cross polarized image were transformed into red images that correlated with hemoglobin absorption/distribution.
Interventions
- BIOLOGICAL Human platelet extract (cosmetic product)
- OTHER Vanicream Gentle Facial Cleanser
- OTHER EltaMD UV Daily Broad-Spectrum SPF 40
- OTHER EltaMD PM Therapy Facial Moisturizer
- OTHER Vanicream Lite Lotion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2022-07-07 |
| Phase | Phase 1 |
Why NCT05457491 stopped before completion
NCT05457491 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which Human platelet extract (cosmetic product) is the first listed.
NCT05457491 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05457491 about?
NCT05457491 is a clinical study titled "Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE)". The Researchers are trying to study a cosmetic skin care product called human platelet extract (HPE) to see if it can be used as a possible treatment for skin anti-aging and skin rejuvenation. They are trying find out the safety and tolerability of topical HPE after multiple doses of topical adminis...
What is the current status of trial NCT05457491?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2021-10-01. Estimated completion is 2022-07-07.
What interventions are being tested in trial NCT05457491?
The interventions under investigation include: Human platelet extract (cosmetic product) (BIOLOGICAL), Vanicream Gentle Facial Cleanser (OTHER), EltaMD UV Daily Broad-Spectrum SPF 40 (OTHER), EltaMD PM Therapy Facial Moisturizer (OTHER), Vanicream Lite Lotion (OTHER).
Who is sponsoring clinical trial NCT05457491?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05457491's enrollment target sits among peer trials
56 902nd of 2000 higher than 1,083 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI